What are the recommended medications and procedural steps for a patient undergoing percutaneous coronary intervention (PCI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Recommended Medications and Procedural Steps for PCI

For patients undergoing PCI, administer intravenous unfractionated heparin (UFH) 70-100 U/kg to achieve an ACT of 250-300 seconds, combined with aspirin (150-300 mg oral or 75-250 mg IV if not pre-treated) and a P2Y12 inhibitor loading dose (clopidogrel 600 mg for elective PCI, or prasugrel/ticagrelor for ACS), with consideration of GP IIb/IIIa inhibitors for high-risk situations. 1, 2

Anticoagulation During PCI

Primary Anticoagulant Choice

UFH remains the standard anticoagulant for PCI procedures 1, 2:

  • Dosing: 70-100 U/kg bolus to achieve target ACT 250-300 seconds 1
  • If patient received prior anticoagulation, give additional UFH as needed to reach target ACT 1

Alternative Anticoagulants

Bivalirudin is a useful alternative with specific advantages 1:

  • For STEMI: Reduces mortality and bleeding compared to UFH (Class I, Level B-R) 1
  • For NSTE-ACS: May reduce bleeding (Class IIb, Level B-R) 1
  • Dosing: 0.75 mg/kg bolus, then 1.75 mg/kg/h IV infusion during procedure 1
  • Post-PCI infusion for primary PCI: Continue 1.75 mg/kg/h for 2-4 hours 1
  • Renal adjustment: Reduce to 1 mg/kg/h if CrCl <30 mL/min 1

Enoxaparin may be considered as an alternative 1, 2:

  • Dosing for PCI support: 0.5-0.75 mg/kg IV bolus if no prior anticoagulation 1
  • If last subcutaneous dose was 8-12 hours prior: give 0.3 mg IV 1
  • If last dose within 8 hours: no additional dose needed 1

Critical caveat: Fondaparinux should NOT be used to support PCI due to catheter thrombosis risk (Class III Harm) 1

Antiplatelet Therapy

Pre-Procedural Loading

Aspirin 1, 2:

  • Loading dose: 150-300 mg oral OR 75-250 mg IV if not pre-treated 2
  • Essential before all PCI procedures 2

P2Y12 Inhibitor Selection depends on clinical presentation 2:

For Elective/Stable CAD:

  • Clopidogrel 600 mg loading dose once coronary anatomy is known and PCI decision made (Class I, Level A) 2
  • Pre-treatment may be considered if PCI probability is high (Class IIb) 2

For ACS/High-Risk Situations:

  • Prasugrel or ticagrelor may be considered for specific high-risk scenarios (e.g., history of stent thrombosis, left main stenting) 2

Cangrelor may be considered in P2Y12-inhibitor naïve patients undergoing PCI (Class IIb, Level A) 2

GP IIb/IIIa Inhibitors

Use selectively 2:

  • Should be considered only for bail-out situations in elective PCI (Class IIa, Level C) 2
  • For ACS patients, particularly high-risk features: abciximab or eptifibatide recommended 1

Post-Procedural Management

Dual Antiplatelet Therapy (DAPT)

Standard duration: 6 months of clopidogrel plus aspirin after elective stenting, regardless of stent type (Class I, Level A) 2

Maintenance dosing 2:

  • Clopidogrel: 75 mg daily
  • Aspirin: 75-162 mg daily (lower doses 75-100 mg preferred when combined with other antithrombotics) 1

Extended DAPT considerations 2:

  • For bioresorbable scaffolds: Consider at least 12 months
  • Duration can be shortened (<6 months) or extended (>6-12 months) based on individual bleeding/ischemic risk

Long-Term Therapy

Life-long single antiplatelet therapy (usually aspirin) is recommended after DAPT completion (Class I, Level A) 2

Critical patient education: Instruct patients about the importance of compliance with antiplatelet therapy to prevent stent thrombosis and recurrent MI 2

Key Procedural Considerations

Anticoagulation Continuation

In patients with ACS undergoing revascularization (PCI or CABG) during the same admission, continue parenteral anticoagulation until revascularization to reduce complications (Class I, Level C-LD) 1

Post-Procedural Heparin

Do NOT routinely continue heparin infusion after uncomplicated PCI 1

Common Pitfalls to Avoid

  1. Never use fondaparinux to support PCI—high catheter thrombosis risk 1
  2. Do not prematurely discontinue antiplatelet therapy—risks stent thrombosis 2
  3. Adjust anticoagulant dosing for renal impairment, particularly with bivalirudin and enoxaparin 1
  4. Time enoxaparin supplementation correctly based on last subcutaneous dose 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.